Molinalogo

Measure

2023

Goal

Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)

44.50%

64.90%

Annual Dental Visits (ADV)

NB

54.60%

Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment

31.21%

46.74%

Appropriate Testing for Pharyngitis (CWP)

66.96%

77.56%

Appropriate Treatment for Upper Respiratory Infection (URI)

92.77%

93.08%

Asthma Medication Ratio (AMR) Total

NA

69.41%

Avoidance of Antibiotic Treatment for Acute Bronchitis / Bronchiolitis (AAB)

61.89%

66.19%

Blood Pressure Control (<140/90) for Patients With Diabetes (BPD)

44.77%

68.61%

Breast Cancer Screening (BCS)

NA

55.25%

Cervical Cancer Screening (CCS)

29.44%

59.85%

Childhood Immunization Status (CIS) Combination #10

14.66%

35.04%

Chlamydia Screening in Women (CHL) Total

54.59%

61.07%

Controlling High Blood Pressure (CBP)

45.50%

65.45%

Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

73.61%

80.86%

Eye Exam for Patients With Diabetes (EED)

30.90%

56.20%

Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA) 7-Day Follow-Up Total

19.89%

27.73%

Follow-Up After Emergency Department Visit for Mental Illness (FUM) 7-Day Follow-Up Total

51.45%

46.35%

Follow-Up After Hospitalization for Mental Illness (FUH) 7-Day Follow-Up Total

25.45%

41.03%

Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) 7-Day Follow-Up Total

27.84%

37.31%

Follow-Up for Children Prescribed ADHD Medication (ADD) Continuation and Maintenance Phase

NA

57.90%

Hemoglobin A1c Control for Patients With Diabetes (HBD) HbA1c Control (<8%)

31.14%

55.72%

Immunizations for Adolescents (IMA) Combination #2

28.10%

38.93%

Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) Engagement of AOD Treatment Total

13.17%

16.94%

Kidney Health Evaluation for Patients with Diabetes (KED)

26.37%

38.80%

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Blood Glucose and Cholesterol Testing Total

38.52%

39.01%

Pharmacotherapy for Opioid Use Disorder (POD) Total

23.31%

31.93%

Pharmacotherapy Management of COPD Exacerbation (PCE) Systemic Corticosteroids

60.95%

75.79%

Pharmacotherapy Management of COPD Exacerbation (PCE) Bronchodilator

71.43%

86.96%

Plan All-Cause Readmissions (PCR) Observed-to-Expected Ratio 18-64 Years

199.20%

≤ 92.72%

Prenatal and Postpartum Care (PPC) Timeliness of Prenatal Care

68.13%

86.86%

Prenatal and Postpartum Care (PPC) Postpartum Care

52.31%

80.78%

Prenatal Immunization Status (PRS) Combination Rate

3.28%

25.81

Risk of Continued Opioid Use (COU) 31-Day Total

6.19%

≤ 2.45%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Received Statin Therapy Total

NA

81.64%

Statin Therapy for Patients with Cardiovascular Disease (SPC) Statin Adherence 80% Total

NA

73.63%

Statin Therapy for Patients with Diabetes (SPD) Received Statin Therapy

NA

67.07%

Statin Therapy for Patients with Diabetes (SPD) Statin Adherence 80%

NA

70.37%

Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) Total

63.04%

63.89%

Use of Imaging Studies for Low Back Pain (LBP)

66.91%

75.44%

Use of Opioids at High Dosage (HDO)

11.50%

≤ 2.19%

Use of Opioids from Multiple Providers (UOP) Multiple Prescribers and Multiple Pharmacies

0.72%

≤ 0.87%

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) BMI Percentile

78.59%

83.21%